Table 2. Clinical characteristics of patients with MGUS associated neuropathy.
| MGUS-N N=36 (100%) | |||
|---|---|---|---|
| axonal neuropathy | CIDP | DADS | |
| N (%) | 20 (55) | 10 (28) | 6 (17) |
| Sex f/m | |||
| f (%) | 5 (14) | 2 (6) | 0 (0) |
| m (%) | 15 (42) | 8 (22) | 6 (17) |
| Ig isotype | |||
| IgG | 10 (28) | 7 (19) | 0 (0) |
| IgM | 6 (17) | 2 (6) | 5 (14) |
| IgA | 4 (11) | 1 (3) | 1 (3) |
| Treatment | |||
| Steroids | 3 (8) | 9 (25) | 2 (6) |
| IVIG | 4 (11) | 10 (28) | 4 (11) |
| Rituximab | 2 (6) | 3 (8) | 3 (8) |
| Azathioprine | 0 (0) | 2 (6) | 0 (0) |
| Mycophenolate-Mofetil | 0 (0) | 2 (6) | 0 (0) |
| Lenalidomide | 0 (0) | 1 (3) | 1 (3) |
| Carfilzomib | 0 (0) | 0 (0) | 1 (3) |
| Plasmapheresis | 0 (0) | 2 (6) | 0 (0) |
| Pain therapy | 8 (22) | 7 (19) | 3 (8) |
| Pain | |||
| Yes | 10 (28) | 9 (25) | 4 (11) |
| No | 10 (28) | 1 (3) | 2 (6) |
| Symptoms of neuropathy | |||
| Motor, only | 3 (8) | 0 (0) | 0 (0) |
| Sensory, only | 8 (22) | 0 (0) | 1 (3) |
| Sensorimotor | 8 (22) | 10 (28) | 5 (14) |
| Tremor | 6 (17) | 3 (8) | 2 (6) |
| Not classified | 1 (3) | 0 (0) | 0 (0) |
| Severity of neuropathy | |||
| Mild | 2 (6) | 1 (3) | 1 (3) |
| Moderate | 1 (3) | 4 (11) | 2 (6) |
| Severe | 1 (3) | 5 (14) | 3 (8) |
| Not classified | 16 (44) | 0 (0) | 0 (0) |
DADS, distal acquired demyelinating symmetric neuropathy; CIDP, chronic inflammatory demyelinating polyneuropathy; Ig, Immunoglobulin; IVIG, Intravenous immunoglobulin.